Another method being studied - which also addresses the safety issue - is to deliver IL-1b directly to the tumor.
Wash. U. in St. Louis has published a fair amount of research in this area. Fascinating concept...they use a virus that selectively infects certain cancer tumors and doesn't infect healthy tissue. Using genetic techniques, they've encoded the IL-1b gene in the virus. After the virus is injected into the subject and infects the tumor, the virus pumps out IL-1b.
Here are 3 abstracts that describe this work:
Cancer J Sci Am 1996 Jan;2(1):21
In Vivo Murine Tumor Gene Delivery and Expression by Systemic Recombinant Vaccinia Virus Encoding Interleukin-1beta.
Peplinski GR, Tsung K, Casey MJ, Meko JB, Fredrickson TN, Buller RM, Norton JA
ncbi.nlm.nih.gov
----
Surgery 1995 Aug;118(2):185-190
In vivo gene therapy of a murine pancreas tumor with recombinant vaccinia virus encoding human interleukin-1 beta.
Peplinski GR, Tsung K, Meko JB, Norton JA
ncbi.nlm.nih.gov
----
Ann Surg Oncol 1995 Mar;2(2):151-159
Construction and expression in tumor cells of a recombinant vaccinia virus encoding human interleukin-1 beta.
Peplinski GR, Tsung K, Whitman ED, Meko JB, Norton JA
ncbi.nlm.nih.gov
----
Rudy |
